You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(688180.SH)公佈2022年度業績 研發投入佔營收比例升至164.04%

格隆匯3月30日丨君實生物(688180.SH)披露2022年年度報吿,報吿期內,公司實現營業收入14.53億元,同比減少63.89%,主要繫上期公司基於與Eli Lillyand Company、Coherus的合作協議產生了大額技術許可收入和特許權收入,報吿期內對應的技術許可收入及特許權收入減少;研發投入佔營業收入的比例為164.04%,而上年同期為51.40%。

公司產品以源頭創新、自主研發類生物製品為主,同時通過與國內外優秀的生物科技公司合作進一步豐富產品管線。截至該報吿披露日,公司在研產品管線覆蓋五大治療領域,包括惡性腫瘤、自身免疫系統疾病、慢性代謝類疾病、神經系統類疾病以及感染類疾病。

其中,處於商業化階段的產品共4項(拓益®、君邁康®、民得維®及埃特司韋單抗),近30項在研產品處於臨牀試驗階段(其中昂戈瑞西單抗、貝伐珠單抗以及PARP抑制劑處於III期關鍵註冊臨牀試驗階段),超過20項在研產品處在臨牀前開發階段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account